Response to proposal for a novel cancer drug pricing model

Toon van der Gronde^{1

2}, Hubertus G Leufkens², Toine Pieters³

Affiliations

¹ AstraZeneca, Cambridge, United Kingdom.
² Utrecht Institute for Pharmaceutical Sciences (UIPS) Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, Netherlands.
³ Utrecht Institute for Pharmaceutical Sciences (UIPS) Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, Netherlands. t.pieters@uu.nl.

Comment

Toon van der Gronde et al. Nat Rev Clin Oncol. 2018 Aug.

. 2018 Aug;15(8):528.

doi: 10.1038/s41571-018-0062-7.

Toon van der Gronde^{1

2}, Hubertus G Leufkens², Toine Pieters³

¹ AstraZeneca, Cambridge, United Kingdom.
² Utrecht Institute for Pharmaceutical Sciences (UIPS) Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, Netherlands.
³ Utrecht Institute for Pharmaceutical Sciences (UIPS) Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, Netherlands. t.pieters@uu.nl.

No abstract available

Comment in

Reply to 'Response to proposal for a novel cancer drug pricing model'.
Uyl-de Groot CA, Löwenberg B. Uyl-de Groot CA, et al. Nat Rev Clin Oncol. 2018 Aug;15(8):528-529. doi: 10.1038/s41571-018-0063-6. Nat Rev Clin Oncol. 2018. PMID: 29955113 No abstract available.

Sustainability and affordability of cancer drugs: a novel pricing model.
Uyl-de Groot CA, Löwenberg B. Uyl-de Groot CA, et al. Nat Rev Clin Oncol. 2018 Jul;15(7):405-406. doi: 10.1038/s41571-018-0027-x. Nat Rev Clin Oncol. 2018. PMID: 29735987 No abstract available.